Inhibrx Biosciences
Develops biologic drug candidates led by ozekibart and INBRX-106.
Something off on this page? Send us feedback.
Profile
Develops clinical-stage biologic drug candidates from the post-Sanofi Inhibrx platform, led by ozekibart and INBRX-106. With no marketed products and one reportable segment, the business depends on clinical execution, FDA review, and eventual commercialization.
Develops biologic therapeutic candidates from the post-Sanofi Inhibrx platform, with ozekibart and INBRX-106 as the active clinical programs. The business is organized as one reportable segment and has no marketed products.
Ozekibart is the most advanced asset after FDA acceptance of its biologics license application for unresectable or metastatic conventional chondrosarcoma. INBRX-106 is an OX40 agonist studied with pembrolizumab in head and neck cancer and other solid tumors.
Operates from La Jolla with an R&D-heavy workforce and founder Mark P. Lappe still serving as chief executive. The business depends on clinical execution, FDA review, and eventual commercialization rather than recurring product revenue.
Company facts
Key statistics
Year to date +64.8% · Average volume (30d) 244.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Aug 24, 2026 | H.C. Wainwright | Initiate | Buy | $245 |
| May 15, 2026 | Stifel Nicolaus | Target | $325 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$2.28 | −$2.34 | −2.6% | — | — | — | −8.91% |
| Aug 12, 2026Q2 FY26 | −$2.28 | −$2.34 | −2.6% | — | $0 | — | −1.37% |
| May 14, 2026Q1 FY26 | −$2.37 | −$2.15 | +9.3% | — | — | — | −6.47% |
| Mar 19, 2026Q4 FY25 | −$2.08 | −$2.11 | −1.4% | $1.1M | — | — | −6.09% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $0 | $0 | $0 | $0 | |
| Gross profit | −$675.0K | $638.0K | −$582.0K | −$564.0K | −$537.0K | $0 | |
| Operating income | −$42.9M | −$27.4M | −$33.8M | −$30.9M | −$30.9M | −$32.1M | |
| Net income | −$43.3M | −$28.7M | −$35.3M | −$32.8M | −$33.4M | −$36.7M | |
| Diluted EPS | −$2.80 | −$1.85 | −$2.28 | −$2.11 | −$2.15 | −$2.34 | |
| Gross margin | — | 49.1% | — | — | — | — | |
| Operating margin | — | -2,106.8% | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $7.1M · FY22 $2.2M · FY23 $1.8M · FY24 $200.0K · FY25 $1.3M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $133.3M · Total debt $5.3M · Total assets $154.2M · Shareholders' equity −$53.0M
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 30, 2024 | May 30 | Jun 20 | $0.85 | special dividend |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 14.67M · Float 10.87M · 74.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Perceptive Life Sciences Master Fund, Ltd. | 1.49M | 9.90% | 13G | Nov 14, 2024 |
| Morgan Stanley | 1.31M | 8.92% | 13F | Aug 13, 2026 |
| Perceptive Advisors LLC | 1.30M | 8.85% | 13F | Aug 14, 2026 |
| Sanofi | 1.16M | 7.89% | 13F | Jul 28, 2026 |
| Jon Faiz Kayyem | 1.15M | 7.90% | 13D | Feb 26, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 7, 2025 | Viking Global Investors LP | 10 percent owner | −350,000 | $32.25 |
Peers
- Merck
Keytruda benchmark for first-line HNSCC checkpoint combinations
- Bicara Therapeutics
Late-stage ficerafusp alfa challenger in first-line HNSCC
- Bristol-Myers Squibb
Opdivo checkpoint franchise across HNSCC and solid tumors
- PDS Biotechnology
Versamune HPV checkpoint-combination program in HPV16+ HNSCC
- Cogent Biosciences
Rare solid-tumor precision therapy peer in GIST
- Cue Biopharma
CUE-101 T-cell engager program in HPV16+ HNSCC
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences | $123.41 | −0.19% | $1.81B | — | — | — | −100.0% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Bicara Therapeutics | $23.43 | +0.06% | $1.54B | — | — | — | — |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| PDS Biotechnology | $0.2136 | +2.05% | $11.8M | — | — | — | — |
| Cogent Biosciences | $34.59 | −0.24% | $5.92B | — | — | — | — |
| Cue Biopharma | $27.88 | −1.06% | $73.3M | — | — | 1.9 | +166.7% |
| Median | 66.7 | 13.8 | 2.8 | +5.7% |